UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a safe and well-tolerated profile consistent with... slovenia times več »
Več iz medija
Forest City SFZ Highlights Early JS-SEZ Traction as Investment Pipeline...
Singapore-based companies have committed more than S$5.5 billion in Johor since the JS-SEZ memorandum of understanding, while IMFC-J reported 1,000 enquiries... slovenia times več »
Scara Group targets growing security market with new-generation shelter...
slovenia times več »
#LUXMyWill: Beauty Brand LUX Turns "#BuryMeInThis" From Social Media Trend...
slovenia times več »
Natalie C. Uy Leads University Pad with a Legacy Rooted in Education,...
slovenia times več »
OTP Bank Becomes First EU Financial Institution to Open a EUR 7 Billion...
Rated AAA on the China national scale by Lianhe and recently ranked 398th on Forbes Global 2000, up from 1007th in 2022 · Milestone marked by a gong ceremony... slovenia times več »
Save the Children Hong Kongs Play to Thrive: Prioritising Personal Growth...
slovenia times več »
Competition, Workplace Safety and Financial Pressures Shape Risk Agenda for...
slovenia times več »
No deal as opposition snubs coalitions "development...
slovenia times več »